Novartis AG: Gets a Neutral rating from RBC

Novartis reported that its experimental MS drug, remibrutinib, reduced relapses by about a third compared to Sanofi's Aubagio in late-stage trials, with no liver toxicity signals. The drug showed significant improvements in disability progression and MRI activity. Novartis plans global approval filings for relapsing MS. Shares slipped on Monday.

Novartis reported positive Phase III trial results for remibrutinib, showing 31–35% reduction in MS relapses and a 29.2% reduction in disability progression. The drug demonstrated a favorable safety profile compared to teriflunomide, with lower liver enzyme elevations and fewer adverse event discontinuations. Novartis positions remibrutinib as a potential new treatment for relapsing multiple sclerosis (RMS).

Novartis reported a 19.1% reduction in death risk for early breast cancer patients treated with Kisqali (ribociclib) plus endocrine therapy, per six-year NATALEE trial data. Benefits included a 5.3% invasive disease-free survival increase and a 2.1% overall survival difference. The findings support Kisqali's role in treating high-risk early breast cancer, according to Novartis and trial investigators.

Novartis reported positive late-stage study results for its drug remibrutinib. The company held a special call to discuss the findings. Novartis shares have seen a 16.79% increase year-to-date, trading at 128.00 CHF.

Novartis' MS drug reduced relapse rates by 31.2% to 35.2% vs. teriflunomide, missing analyst expectations of 45%-60%. Roche's rival drug showed a 55% reduction. Novartis' drug showed no liver safety issues, unlike Roche's. Analysts estimate peak sales of $4B if approved. (NVS, RHHBY)

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.